Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)

Dianthus Therapeutics has reported EBITDA Margin over the past 4 years, most recently at 9267.68% for Q3 2025.

  • Quarterly results put EBITDA Margin at 9267.68% for Q3 2025, down 814171.0% from a year ago — trailing twelve months through Sep 2025 was 4121.6% (down 288405.0% YoY), and the annual figure for FY2024 was 1361.83%, up 17204.0%.
  • EBITDA Margin for Q3 2025 was 9267.68% at Dianthus Therapeutics, up from 16477.2% in the prior quarter.
  • Over the last five years, EBITDA Margin for DNTH hit a ceiling of 303.76% in Q3 2022 and a floor of 16477.2% in Q2 2025.
  • Median EBITDA Margin over the past 4 years was 1581.46% (2024), compared with a mean of 3215.17%.
  • Biggest five-year swings in EBITDA Margin: soared 47014bps in 2024 and later crashed -1553158bps in 2025.
  • Dianthus Therapeutics' EBITDA Margin stood at 874.53% in 2022, then plummeted by -163bps to 2300.22% in 2023, then increased by 5bps to 2188.16% in 2024, then plummeted by -324bps to 9267.68% in 2025.
  • The last three reported values for EBITDA Margin were 9267.68% (Q3 2025), 16477.2% (Q2 2025), and 2523.39% (Q1 2025) per Business Quant data.